Want to see JP:4507 full AI Analyst Report?
4507 Stock Chart & Stats
¥2902.50
¥8.00(0.28%)
At close: 4:00 PM EDT
¥2902.50
¥8.00(0.28%)
Day’s Range― - ―
52-Week Range¥2,392.50 - ¥3,758.00
Previous CloseN/A
Volume2.13M
Average Volume (3M)2.56M
Market Cap
¥2.56T
Enterprise Value¥2.76M
Total Cash (Recent Filing)¥298.94B
Total Debt (Recent Filing)¥684.13B
Price to Earnings (P/E)12.1
Beta0.49
Next Earnings
Oct 29, 2026EPS Estimate
39.33Next Dividend Ex-DateN/A
Dividend Yield2.44%
Share Statistics
EPS (TTM)309.64
Shares Outstanding889,632,200
10 Day Avg. Volume2,991,150
30 Day Avg. Volume2,559,626
Financial Highlights & Ratios
PEG Ratio0.71
Price to Book (P/B)1.75
Price to Sales (P/S)5.91
P/FCF Ratio14.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥3,400.00Price Target Upside17.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)249.66
Revenue Forecast (FY)¥699.35B
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained very high gross and net margins (circa 82% and 41%) indicate durable pricing power and a favorable product mix in specialty pharmaceuticals. High margins support ongoing R&D funding, partnership leverage and internal investment, improving long‑term resilience to cost cycles.
Top-line Growth MomentumConsistent double-digit revenue growth (TTM ~12.7%) reflects expanding demand or successful launches and strengthens the company’s ability to fund development and commercialization. Persistent top-line momentum supports scale advantages and long-term competitive positioning in key therapeutic areas.
Strong Free Cash Flow ConversionHigh free cash flow conversion (~93% of net income) shows profit quality and reliable internal funding for dividends, R&D and partnering. Over months this enhances capital allocation flexibility and reduces reliance on external financing for strategic investments and product launches.
Bears Say
Rising LeverageA material increase in leverage versus prior years alters the capital structure and reduces financial flexibility. Higher debt raises interest exposure and constrains strategic optionality (M&A, licensing), elevating execution risk if operating cash flows soften or reimbursement pressure intensifies.
Weak Cash Coverage Of DebtOperating cash flow covering only ~0.26x of total debt signals limited ability to service obligations from core operations. This weak coverage increases refinancing risk and constrains buffer for R&D or unexpected costs, making the firm more sensitive to revenue shocks over the medium term.
Portfolio Concentration & Margin VolatilityDependence on a limited number of branded medicines means commercial or patent setbacks and price/reimbursement changes can disproportionately affect revenue and margins. Historical margin volatility suggests earnings can swing with product mix or one‑off items, reducing predictability of long‑term cash flows.
Shionogi & Co News
4507 FAQ
What was Shionogi & Co Ltd’s price range in the past 12 months?
Shionogi & Co Ltd lowest stock price was ¥2392.50 and its highest was ¥3758.00 in the past 12 months.
What is Shionogi & Co Ltd’s market cap?
Shionogi & Co Ltd’s market cap is ¥2.56T.
When is Shionogi & Co Ltd’s upcoming earnings report date?
Shionogi & Co Ltd’s upcoming earnings report date is Oct 29, 2026 which is in 82 days.
How were Shionogi & Co Ltd’s earnings last quarter?
Shionogi & Co Ltd released its earnings results on Aug 03, 2026. The company reported ¥114.81 earnings per share for the quarter, beating the consensus estimate of ¥46.535 by ¥68.275.
Is Shionogi & Co Ltd overvalued?
According to Wall Street analysts Shionogi & Co Ltd’s price is currently Undervalued.
Does Shionogi & Co Ltd pay dividends?
Shionogi & Co Ltd pays a Semiannually dividend of ¥38 which represents an annual dividend yield of 2.44%. See more information on Shionogi & Co Ltd dividends here
What is Shionogi & Co Ltd’s EPS estimate?
Shionogi & Co Ltd’s EPS estimate is 39.33.
How many shares outstanding does Shionogi & Co Ltd have?
Shionogi & Co Ltd has 889,632,200 shares outstanding.
What happened to Shionogi & Co Ltd’s price movement after its last earnings report?
Shionogi & Co Ltd reported an EPS of ¥114.81 in its last earnings report, beating expectations of ¥46.535. Following the earnings report the stock price went down -0.344%.
Which hedge fund is a major shareholder of Shionogi & Co Ltd?
Currently, no hedge funds are holding shares in JP:4507
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shionogi & Co Ltd
Shionogi & Co., Ltd. (4507) is a Japan-based research-driven pharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. The company’s business is centered on ethical pharmaceuticals, with a portfolio that includes treatments in areas such as infectious diseases and other therapeutic fields, and it supports these activities through related functions such as drug development, manufacturing, and marketing.
4507 Stock 12 Month Forecast
Average Price Target
¥3,400.00
▲(17.14% Upside)
Technical Analysis
Sumitomo Dainippon Pharma Co
―
Eisai Co
―
―
Takeda Pharmaceutical Co
―
Nippon Shinyaku Co., Ltd.
―







